Pediatric Population Screening for Type 1 Diabetes and Familial Hypercholesterolemia in Lower Saxony, Germany

Type 1 Diabetes Clinical Trial

— Fr1dolin  

Official title:

Pediatric Population Screening for Type 1 Diabetes and Familial Hypercholesterolemia in Lower Saxony, Germany

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02750527
• Other study ID #: H-Fr1dolin-01
• Status: Completed
• Start date: September 2016
• Est. completion date: December 2020

Study information

• Verified date: June 2021
• Source: Kinderkrankenhaus auf der Bult
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a Pilot/ feasibility study for a population-based Screening in all children 2 to 6 years in Lower Saxony, Germany during the compulsory (U7 (from the age of 2) U7a, U8, U9) routine check-ups and any voluntary visits to the pediatricians office.

Description:

The Fr1dolin-Study will be presented to the parents of ca. 320,000 children living in Lower Saxony, Germany. The recruitment of subjects, collection of written consent, the capillary blood sample and the screening questionnaire will be done by the registered pediatricians in their local medical practices. After study enrolment 200 µl of capillary blood are be taken from the subject and are sent pseudo-anonymized to the lab. LDL-C and the diabetes-associated antibodies are identified. Based on the results a second blood sample will be required. In case of pre-type-1 diabetes or signs for a familial hypercholesterolemia the pediatrician will be informed. He will contact the parents and discuss the further procedure in cooperation with the study center. In case of a positive result by measuring diabetes-related antibodies and LDL-C the goal of this trial is to advise and educate the families appropriate and to treat them if necessary. In addition families should have the possibility to participate in prevention trials. All data will be registered in a study database. Follow-up pre-type 1 diabetes: During the first year, follow-up will be performed after 6 and 12 months and thereafter annually until the age of 12 years or up to 6 months after the clinical onset of type 1 diabetes. Follow-up familial hypercholesterolemia: During the first year, follow-up will be performed after 6 and 12 months and thereafter annually until the age of 12 years.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 13049
• Est. completion date: December 2020
• Est. primary completion date: December 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 2 Years to 6 Years

Eligibility

Inclusion Criteria:

• Children living in Lower Saxony (primary residence)
• Age between 2 and 6 years (both included)
• Written consent by at least one parent / legal representative
• Willingness to deliver 200 µl of capillary blood
• Willingness to complete a questionnaire
• Willingness to participate to the follow-up visits

Exclusion Criteria:

• none

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 1
• Familial Hypercholesterolemia
• Hypercholesterolemia
• Hyperlipoproteinemia Type II
• Type 1 Diabetes

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Kinderkrankenhaus auf der Bult

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	number of familial hypercholesterolemia or pre-type-1-diabetes	identification of patients/ families with familial hypercholesterolemia or pre-type-1 diabetes	18 month